A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

NCT01684215 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Breast Neoplasms

Interventions

DRUG: PD-0332991
DRUG: PD-0332991
DRUG: letrozole
DRUG: PD-0332991
DRUG: letrozole

Sponsor

Pfizer